MapLight Therapeutics (MPLT) Interest & Investment Income (2024 - 2025)
MapLight Therapeutics recorded quarterly Interest & Investment Income of $2.5 million in Q4 2025, up 59.46% quarter-over-quarter from $1.5 million in Q3 2025, and up 174.75% year-over-year from $899000.0 in Q4 2024.
MapLight Therapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $2.5 million for Q4 2025.
- In Q4 2025, Interest & Investment Income rose 174.75% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $6.0 million (changed N/A YoY), while the FY2025 annual figure was $5.5 million, up 22.51% from the prior year.
- Interest & Investment Income came in at $2.5 million for Q4 2025 at MapLight Therapeutics, up from $1.5 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.5 million in Q4 2025 to a low of $899000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 2.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.47 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Dec 31, 2024 | 899,000.00 |
| Sep 30, 2024 | 1.08 Mn |